Literature DB >> 19333607

Preoperative use of epoietin beta in total hip replacement: a prospective study.

Jean-Michel Laffosse1, Vincent Minville, Philippe Chiron, Aline Colombani, Claude Gris, Jean-Claude Pourrut, Bernard Eychenne, Olivier Fourcade.   

Abstract

OBJECTIVE: Epoietin (EPO) effectively decreases perioperative blood transfusion requirements. We evaluated the feasibility of using EPO beta to increase haemoglobin levels before total hip replacement (THR) and reduce transfusion.
MATERIALS AND METHODS: One hundred and seventy-one patients undergoing primary THR were included in this prospective observational study. Patients with initial haemoglobin level <130 g l−1 received EPO beta subcutaneously in a four-dose regimen. Haemoglobin levels were measured at baseline, before surgery, and at postoperative days 1 and 5.
RESULTS: Twenty-eight patients received EPO beta preoperatively, 143 were not treated including 42 with initial haemoglobin level <130 g l−1. Haemoglobin increased by 29 ± 9 g l−1 in the low Hb + EPO group versus 2 ± 1 g l−1 for the other patients. In the low Hb + EPO group 3.6% were transfused, in the low HB group 45.2% (P = 0.001) and in the normal Hb group 11.9% (P = 0.2).
CONCLUSIONS: Preoperative EPO beta increases haemoglobin level and reduces transfusion frequency in anaemic patients before total joint replacement. It could play a major role in the management of perioperative blood loss in orthopaedic surgery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19333607     DOI: 10.1007/s00402-009-0863-3

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  5 in total

1. 

Authors:  Berrin Günaydın; Ömer Kurtipek
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-06-01

2.  Blood transfusion in hip and knee arthroplasties: the end of the pre-operative group and save?

Authors:  B A Marson; J Shah; M Deglurkar
Journal:  Eur J Orthop Surg Traumatol       Date:  2015-01-30

3.  Topical tranexamic acid reduces blood loss and transfusion rates associated with primary total hip arthroplasty.

Authors:  Chih-Hsiang Chang; Yuhan Chang; Dave W Chen; Steve W N Ueng; Mel S Lee
Journal:  Clin Orthop Relat Res       Date:  2014-01-03       Impact factor: 4.176

4.  [Perioperative blood management for total hip/knee arthroplasty].

Authors:  Mingcheng Yuan; Zichuan Ding; Tingxian Ling; Zongke Zhou
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-12-15

5.  Finding the optimal regimen for short-term daily recombinant human erythropoietin treatment for blood-saving purpose in patients undergoing unilateral primary total hip arthroplasty: a double-blinded randomized placebo-controlled trial.

Authors:  Mingcheng Yuan; Qifeng Tao; Duan Wang; Haoyang Wang; Zongke Zhou
Journal:  BMC Musculoskelet Disord       Date:  2022-03-12       Impact factor: 2.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.